网红黑料

Skip to main content
(352) 733-0111

20432A - Protocol - Edition 1.0

  • Status
    Accepting Candidates
  • Age
    40 Years - 75 Years
  • Sexes
    All
  • 网红黑料y Volunteers
    No
I'm interested
Share this study

Objective

To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

Description

This study will consist of a double-blind period (DBP) and will include an optional open-label treatment extension (OLE) period. Participants in the DBP will be randomized to Lu AF82422 or placebo (2:1). All participants entering the OLE will receive Lu AF82422 during the OLE.

Details

Full study title Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy
Protocol number OCR46921
ClinicalTrials.gov ID NCT05104476
Phase Phase 2

Eligibility

Key Inclusion Criteria:

  • The participant is diagnosed with possible or probable MSA of the multiple system atrophy parkinsonian type (MSA-P) or multiple system atrophy cerebellar type (MSA-C) sub-type at the Screening Visit.

  • The participant had onset of motor and/or autonomic (orthostatic or urinary) MSA symptoms within 5 years prior to the Screening Visit in the judgement of the investigator.

  • The participant has an UMSARS Part I score 鈮�16 (omitting item 11 on sexual function) at the Screening Visit.

  • The participant has a cognitive performance evaluated by the Montreal Cognitive Assessment (MoCA) with a score 鈮�22 at the Screening Visit.

Open-label Extension Entry Criteria

  • The participant has completed the EoT Visit and did not withdraw in the DBP.

  • The participant has consented to participate in the OLE.

  • The participant has completed the DBP within the last 5 months and will be enrolled into the OLE no later than end of Q1 2024.

  • The participant is, in the Investigator's opinion, likely to comply with the protocol.

  • The participant has not received any other Investigational product since the EOoTDBP Visit.

Key Exclusion Criteria:

  • The participant has been treated with an anti-伪-synuclein monoclonal antibody, mesenchymal stem cells or an inhibitor of 伪-synuclein aggregation within the last 12 months.

  • The participant has any past or current treatment with an active vaccine targeting 伪-synuclein.

  • The participant has 2 or more blood relatives with a history of MSA.

  • The participant has evidence (clinically or on MRI) and/or history of any clinically significant disease or condition other than MSA (for example, serious neurological disorder, other intracranial disease, or systemic disease).

  • The participant has a current diagnosis of movement disorders that could mimic MSA (for example, Parkinson' disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic paraparesis, corticobasal degeneration, or vascular, pharmacological, or post-encephalitic parkinsonism), per investigator discretion.

Other inclusion and exclusion criteria may apply.

Lead researcher

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step
    1

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step
    2

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step
    3

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step
    4

    Participate

    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.